

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**CStone Pharmaceuticals**  
**基石藥業**

(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 2616)

**POLL RESULTS OF ANNUAL GENERAL MEETING  
HELD ON JUNE 23, 2026**

References are made to the notice of annual general meeting (the “AGM Notice”) and the circular (the “AGM Circular”) of CStone Pharmaceuticals (the “Company”) both dated June 1, 2026 and the supplemental announcement of the Company dated June 16, 2026. The board of directors (the “Board”) of the Company is pleased to announce that all the resolutions (the “Resolutions”) set out in the AGM Notice were duly passed by the shareholders of the Company (the “Shareholders”) as ordinary resolutions by way of poll at the annual general meeting of the Company held on June 23, 2026 (the “AGM”). Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the AGM Circular.

The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors (“Directors”) and auditor of the Company for the year ended December 31, 2025	339,485,240 (100.000000%)	0 (0.000000%)	339,485,240 (100.000000%)
2.	(i) To re-elect Dr. Jianxin Yang as an executive Director	338,050,828 (99.577474%)	1,434,412 (0.422526%)	339,485,240 (100.000000%)
	(ii) To re-elect Mr. Kenneth Walton Hitchner III as a non-executive Director	334,959,699 (98.666940%)	4,525,541 (1.333060%)	339,485,240 (100.000000%)
	(iii) To re-elect Mr. Edward Hu as a non-executive Director	334,959,699 (98.666940%)	4,525,541 (1.333060%)	339,485,240 (100.000000%)
	(iv) To re-elect Mr. Kenneth Howard Jarrett as an independent non-executive Director	339,042,666 (99.869634%)	442,574 (0.130366%)	339,485,240 (100.000000%)
	(v) To re-elect Ms. Fang Xie as an independent non-executive Director	339,042,666 (99.869634%)	442,574 (0.130366%)	339,485,240 (100.000000%)
	(vi) To re-elect Ms. Catherine Yen as an independent non-executive Director	339,485,240 (100.000000%)	0 (0.000000%)	339,485,240 (100.000000%)

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
3.	To authorise the board of Directors to fix the remuneration of the Directors	339,321,240 (99.951692%)	164,000 (0.048308%)	339,485,240 (100.000000%)
4.	To re-appoint Deloitte Touche Tohmatsu as auditor of the Company and authorise the board of Directors to fix their remuneration	305,744,044 (90.061071%)	33,741,196 (9.938929%)	339,485,240 (100.000000%)
5.	To grant a general mandate to the Directors to allot, issue and deal with additional shares (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the total issued shares of the Company (excluding any treasury shares of the Company)	293,474,312 (86.446855%)	46,010,928 (13.553145%)	339,485,240 (100.000000%)
6.	To grant a general mandate to the Directors to buy back shares not exceeding 10% of the total issued shares of the Company (excluding any treasury shares of the Company)	339,485,240 (100.000000%)	0 (0.000000%)	339,485,240 (100.000000%)
7.	To extend the authority given to the Directors pursuant to ordinary resolution no. 5 to issue shares by adding to the issued shares of the Company the number of shares bought back under ordinary resolution no. 6	294,506,812 (86.750992%)	44,978,428 (13.249008%)	339,485,240 (100.000000%)
8.	To consider and approve the grant of 7,000,000 Share Options and 4,270,000 RSUs to Dr. Jianxin Yang, an executive director and the chief executive officer of the Company	288,369,874 (86.943273%)	51,115,366 (15.056727%)	339,485,240 (100.000000%)

*Notes:*

- As more than 50% of the votes were cast in favour of each of the Resolutions numbered 1 to 8, the Resolutions numbered 1 to 8 proposed at the AGM were duly passed as ordinary resolutions of the Company.
- The full text of the Resolutions is set out in the AGM Notice.
- As at the date of the AGM, (i) the total number of ordinary Shares in issue was 1,600,749,183 Shares; (ii) the Company did not hold any treasury shares (which shall have the meaning ascribed to it under the Listing Rules); and (iii) there were 3,336,000 Shares repurchased by the Company were pending cancellation, which, for the purpose of the AGM, were excluded from the total number of issued Shares entitled to attend and vote at the AGM, and the Company did not exercise any voting rights attached to those repurchased Shares. Accordingly, the total number of Shares entitling the Shareholders to attend the AGM and vote for or against or abstain from voting on the Resolutions was 1,597,413,183.

A total of 5,093,520 Shares held by the trustee of the Pre-IPO Incentivization Plan and the Post-IPO RSU Scheme as at the date of the AGM were required to abstain from voting on the Resolutions proposed at the AGM pursuant to Rule 17.05A of the Listing Rules.

As at the date of the AGM, to the best knowledge of the Directors after making reasonable enquiry, Dr. Yang was interested in 72,739,642 Shares including (i) 20,651,308 Shares beneficially held by Dr. Yang under his own name; (ii) 49,639,959 share options granted to him under the Post-IPO ESOP (not including the 7,000,000 Share Options conditionally granted to Dr. Yang), subject to the vesting and other conditions of those share options; and (iii) 2,448,375 RSUs granted to him under the Post-IPO RSU Scheme (not including the 4,270,000 RSUs conditionally granted to Dr. Yang), subject to vesting conditions, representing in aggregate approximately 4.54% of the total issued Shares of the Company (excluding treasury Shares), were required to abstain from voting in favor on the Resolution numbered 8 proposed at the AGM. None of Dr. Yang's respective associates, as prescribed under the Listing Rules, holds any Shares.

As at the date of the AGM, to the best knowledge of the Directors after making reasonable enquiry, other than Dr. Yang, core connected persons of the Company who are Shareholders, namely (i) WuXi Healthcare Ventures II, L.P., a substantial shareholder of the Company which directly held 173,381,444 Shares, representing approximately 10.83% of the total issued Shares of the Company (excluding treasury Shares); (ii) Dr. Wei Li ("**Dr. Li**"), a non-executive Director and the Chairman, who was interested in 2,250,000 Shares including 1,229,159 Shares beneficially held by Dr. Li under his own name, 500,004 share options granted to him under the Post-IPO ESOP and 520,837 RSUs granted to him under the Post-IPO RSU Scheme, representing approximately 0.14% of the total issued Shares of the Company (excluding treasury Shares); (iii) Mr. Edward Hu ("**Mr. Hu**"), a non-executive Director, who was interested in 3,721,000 Shares including 2,200,163 Shares beneficially held by Mr. Hu under his own name, 1,000,000 share options granted to him under the Post-IPO ESOP and 520,837 RSUs granted to him under the Post-IPO RSU Scheme, representing approximately 0.23% of the total issued Shares of the Company (excluding treasury Shares); (iv) Mr. Kenneth Walton Hitchner III ("**Mr. Hitchner**"), a non-executive Director, who beneficially held 2,513,481 Shares under his own name, representing approximately 0.16% of the total issued Shares of the Company (excluding treasury Shares); and (v) Ms. Fang Xie ("**Ms. Xie**"), an independent non-executive Director, who beneficially held 8,500 Shares under her own name, were required to abstain from voting in favor on the Resolution numbered 8 proposed at the AGM.

To the extent the Company is aware and having made all reasonable enquiries, Dr. Yang, WuXi Healthcare Ventures II, L.P., Dr. Li, Mr. Hu, Mr. Hitchner and Ms. Xie, holding in aggregate 254,614,067 Shares (comprising issued Shares, share options and RSUs), representing approximately 15.91% of the total issued Shares of the Company (excluding treasury Shares), were required to abstain from voting in favor on the Resolution numbered 8 proposed at the AGM.

Save as disclosed above, to the best of the knowledge, information and belief of the Board, and having made all reasonable enquiries:

- (i) there were no Shareholders who were entitled to attend the AGM but was required to abstain from voting in favor of the Resolutions proposed at the AGM as set out in Rule 13.40 of the Listing Rules;
  - (ii) none of the Shareholders was required under the Listing Rules to abstain from voting on any of the Resolutions proposed at the AGM; and
  - (iii) there was no restriction on any Shareholders to cast votes on any of the Resolutions proposed at the AGM and none of the Shareholders have stated their intention in the circular of the Company dated June 1, 2026 to vote against or to abstain from voting on any of the Resolutions at the AGM.
4. Computershare Hong Kong Investor Services Limited, the Company's Hong Kong share registrar, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.
  5. The following Directors attended the AGM: Dr. Wei Li, Dr. Jianxin Yang, Mr. Kenneth Walton Hitchner III, Mr. Edward Hu, Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen.

By Order of the Board  
**CStone Pharmaceuticals**  
**Dr. Wei Li**  
*Chairman*

Hong Kong, June 23, 2026

*As at the date of this announcement, the Board of Directors comprises Dr. Wei Li as Chairman and non-executive Director, Dr. Jianxin Yang as executive Director, Mr. Kenneth Walton Hitchner III and Mr. Edward Hu as non-executive Directors, and Mr. Kenneth Howard Jarrett, Ms. Fang Xie and Ms. Catherine Yen as independent non-executive Directors.*